M. Ahn

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

J. Choi, M. Ahn, Joungho Han, 2020, PloS one.

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, Cancer.

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin-naive patients with extensive-disease small cell lung cancer (Cancer (2009) 116, (132-136))

Dong Han Lee, M. Ahn, C. Suh, 2010 .

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

M. Ahn, T. Mok, Yi-long Wu, 2019, Cancer.

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2010, Cancer.

Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use.

M. Ahn, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

M. Ahn, Yi-long Wu, E. Felip, 2014 .

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

M. Ahn, Joungho Han, Yoon-La Choi, 2017, Journal of pathology and translational medicine.

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017, The Lancet. Respiratory medicine.

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

M. Ahn, Dong-Wan Kim, J. Yang, 2016, Science Translational Medicine.

Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer.

M. Ahn, M. H. Park, I. S. Kim, 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-kappaB-independent pathways.

Jung Mogg Kim, M. Ahn, Y. Oh, 2005, International immunology.

Escherichia coli up‐regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34+ stem cells via p50 homodimeric NF‐κB

M. Ahn, Y. Oh, J. M. Kim, 2004, Clinical and experimental immunology.

The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke

Hee-Jin Kim, M. Ahn, Gyeong-Moon Kim, 2021, Journal of clinical medicine.

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Nayoung K. D. Kim, Jung-Il Lee, Y. Suh, 2020, Nature Communications.

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2010, Lung cancer.

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

M. Ahn, Yi-long Wu, Dong-Wan Kim, 2021, JTO Clinical and Research Reports.

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma

M. Ahn, Y. Shim, Jhingook Kim, 2017, World Journal of Surgery.

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery

M. Ahn, Keunchil Park, Y. Shim, 2016, Oncotarget.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

M. Ahn, Keunchil Park, S. Thongprasert, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

ERCC1 expression as a prognostic marker in N2(+) nonsmall‐cell lung cancer patients treated with platinum‐based neoadjuvant concurrent chemoradiotherapy

J. Ahn, M. Ahn, Keunchil Park, 2008, Cancer.

Phase II Study of O xaliplatin , 5-fluorouracil , and Leucovorin in Relapsed or

M. Ahn, Junghye Choi, I. Kim, 2009 .

Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy.

M. Ahn, Junghye Choi, I. Kim, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy.

M. Ahn, Y. Won, Junghye Choi, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study.

M. Ahn, Junghye Choi, O. Lee, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5-Fluorouracil-Pretreated Patients with Metastatic Colorectal Cancer.

M. Ahn, E. Cho, J. Lee, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

S. J. Lee, Joon-Oh Park, M. Ahn, 2017, Investigational New Drugs.

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical Cancer Research.

Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.

M. Ahn, Junghye Choi, O. Lee, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

P. Jänne, M. Ranson, M. Ahn, 2014 .

Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2008, Investigational New Drugs.

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Yong Soo Choi, M. Ahn, Keunchil Park, 2018, Radiation Oncology.

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

J. Ahn, M. Ahn, Keunchil Park, 2020, Nature Communications.

Current Status and Challenges of Cancer Clinical Trials in Korea

M. Ahn, S. Park, Yoon-Koo Kang, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria

Ho Yun Lee, M. Ahn, Keunchil Park, 2010, Korean journal of radiology.

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma

Jae Woo Choi, M. Ahn, S. Lim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute

J. Ahn, M. Ahn, Keunchil Park, 2013, Medical Oncology.

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Kyung Soo Lee, Myung-Ju Ahn, Ho Yun Lee, 2016, Cancer Imaging.

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?

Jae-Hun Kim, Kyung Soo Lee, Yoon-La Choi, 2014, PloS one.

New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.

Kyung Soo Lee, Chin A Yi, Myung Jin Chung, 2011, Lung cancer.

MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).

P. Jänne, N. Hanna, E. Smit, 2013 .

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy

J. Choi, M. Ahn, Keunchil Park, 2015, Clinical and experimental otorhinolaryngology.

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.

Ho Yun Lee, J. Ahn, M. Ahn, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2012, Yonsei medical journal.

ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

M. Ahn, Keunchil Park, T. Mok, 2012 .

Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Lung cancer.

Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system.

J. Choi, J. Ahn, M. Ahn, 2013, Lung cancer.

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.

M. Ahn, E. Choi, S-H. Jung, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of concurrent thoracic radiotherapy with either fi rst-or third-cycle chemotherapy for limited-disease small-cell lung cancer †

M. Ahn, E. Choi, S-H. Jung, 2013 .

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.

N. Hanna, R. Kaiser, M. Ahn, 2016, Lung cancer.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria.

J. Ahn, M. Ahn, Keunchil Park, 2016, Lung cancer.

A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

M. Ahn, I. Do, Y. Won, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

J. Ahn, M. Ahn, Keunchil Park, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras

J. Ahn, M. Ahn, Keunchil Park, 2009, Oncology.

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

T. Mitsudomi, M. Ahn, Keunchil Park, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer

Su Jin Lee, S. J. Lee, M. Ahn, 2021, Cancer research and treatment.

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

H. Groen, A. Chella, M. Ahn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An indirect comparison of bevacizumab plus cisplatin‐gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first‐line non‐squamous non‐small cell lung cancer in East Asia

M. Ahn, S. Thongprasert, S. Walzer, 2011, Asia-Pacific journal of clinical oncology.

Predictive Value of 18F-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer

Yong Soo Choi, J. Choi, M. Ahn, 2022, Cancers.

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.

Y. S. Kim, Sin-Ho Jung, M. Ahn, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

H. Seol, Jung-Il Lee, D. Kong, 2020, Journal of Korean Neurosurgical Society.

Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.

M. Ahn, A. Nagrial, M. Satouchi, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Immunotherapy for Cancer.

Organ Preservation for the Management of Locally Advanced Head and Neck Cancer

M. Ahn, 2009 .

Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Ko, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).

Hung-Ming Wang, M. Ahn, B. Solomon, 2014 .

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Gettinger, S. Ou, 2012 .

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Yong Soo Choi, J. Ahn, M. Ahn, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer

M. Ahn, Yi-long Wu, M. Orlando, 2016, Asia-Pacific journal of clinical oncology.

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

P. Jänne, C. Ki, J. Ahn, 2008, Clinical Cancer Research.

Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer ?

C. Ki, J. Ahn, M. Ahn, 2008 .

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The Continuation of Erlotinib Treatment in Non-Small Cell Lung Cancer Patients Whose Brain Lesion Is the Only Site of Progression: Prospective Pilot Study

J. Ahn, M. Ahn, Keunchil Park, 2015 .

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

S. Paik, M. Ahn, B. Cho, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

J. Ahn, M. Ahn, Keunchil Park, 2016, Cancer.

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer.

Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2011, International journal of radiation oncology, biology, physics.

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

M. Ahn, S. K. Lee, Y. Son, 2008, British Journal of Cancer.

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

J. Ahn, M. Ahn, Keunchil Park, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT

M. Ahn, J. Yang, R. Cheng, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Ho Yun Lee, J. Ahn, M. Ahn, 2016, Journal of thoracic disease.

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.

J. Ahn, M. Ahn, Keunchil Park, 2015, Pharmacogenomics.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy

Joon-Oh Park, J. Ahn, M. Ahn, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats

J. Ahn, M. Ahn, Keunchil Park, 2011, Cancer Chemotherapy and Pharmacology.

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

F. Hirsch, J. Ahn, M. Ahn, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.

Su Jin Lee, S. J. Lee, J. Ahn, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

M. Ahn, E. Cho, B. Cho, 2021, JTO clinical and research reports.

ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

H. Groen, G. Scagliotti, H. Wakelee, 2015 .

Protein Expression in Prim ary C olorectal C ancer for Predicting Response to 5-fluorouracil-based C hem otherapy

M. Ahn, K. Song, Junghye Choi, 2009 .

Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy.

M. Ahn, K. Song, Junghye Choi, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

A Randomized Trial Comparing Cisplatin Plus 5-fluorouracil With or Without Levamisole in Operable Gastric Cancer

M. Ahn, Jung Shin Lee, Woojun Kim, 1997, The Korean journal of internal medicine.

A Case of Primary Intestinal T-Cell Lymphoma Involving Entire Gastrointestinal Tract: Esophagus to Rectum

M. Ahn, Moon-Hyang Park, B. Yoon, 2000, The Korean Journal of Internal Medicine.

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery

Yong Soo Choi, M. Ahn, Keunchil Park, 2015, Journal of thoracic disease.

LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA (NSCLC)

M. Ahn, S. Ramalingam, K. Emancipator, 2014 .

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

J. Zell, A. Ziogas, J. Ahn, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

A. Drilon, M. Ahn, A. Wozniak, 2018, Cancer discovery.

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Reply to B.M. Strebel.

H. Groen, M. Ahn, J. Aerts, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2020, Lung cancer.

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic disease.

Severe Health-care Associated Pneumonia among the Solid Cancer Patients on Chemotherapy

S. Park, J. Ahn, M. Ahn, 2009 .

Association of the methylenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia.

M. Ahn, E. Cho, N. Kim, 2006, Anticancer research.

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Oncotarget.

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

M. Ahn, I. Do, Y. L. Choi, 2013, British Journal of Cancer.

A Case of Primary Plasmacytoma of Lymph Nodes

M. Ahn, Junghye Choi, Su Kyoung Park, 2005, The Korean journal of internal medicine.

Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Scientific Reports.

J. Ahn, M. Ahn, Keunchil Park, 2020, Oncoimmunology.

Telomerase activity and its clinicopathological significance in gastric cancer.

M. Ahn, Y. S. Lee, Y. Noh, 1997, European journal of cancer.

Therapeutic efficacy of Cancer vaccine Adjuvanted with Nanoemulsion loaded with TLR7/8 agonist in lung Cancer model.

J. Ahn, M. Ahn, Keunchil Park, 2021, Nanomedicine : nanotechnology, biology, and medicine.

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea

M. Ahn, Keunchil Park, M. Kwon, 2020, BMC Cancer.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.

J. Ahn, M. Ahn, Yoon-La Choi, 2022, European journal of cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

J. Ahn, M. Ahn, Yoon-La Choi, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Yeon Jeong Kim, J. Ahn, M. Ahn, 2022, Oncology.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of Malignant Cells in Pleural Fluid or Ascites by CD44v8-10/CD44v10 competitive RT-PCR

M. Ahn, Jang-Won Sohn, Y. Noh, 2001, The Korean journal of internal medicine.

A Randomized Double‐Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin‐Based Chemotherapy

M. Ahn, C. Suh, Jung Shin Lee, 1994, American journal of clinical oncology.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

J. Ahn, M. Ahn, Dong-Wan Kim, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Sung Sook Lee, M. Ahn, E. Cho, 2020 .

Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review

M. Ahn, Keunchil Park, Hyung-Jin Kim, 2020, Head & neck.

Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature.

Yong Soo Choi, M. Ahn, Joungho Han, 2017, Pathology, research and practice.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of immunology.

Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

M. Ahn, R. Mehra, R. Swaby, 2021 .

Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?

M. Ahn, Jiyun Lee, 2020, Current opinion in oncology.

R. Herbst, M. Ahn, E. Felip, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer.

M. Ahn, 2018, Journal of thoracic disease.

Clues to Occult Cancer in Patients with Ischemic Stroke

M. Ahn, O. Bang, Jae Hyun Park, 2012, PloS one.

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Jie Yang, N. Pavlakis, Y. Yatabe, 2022, Clinical lung cancer.

Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

M. Ahn, H. Saka, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

459PRisk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001

M. Ahn, S. Ramalingam, M. Hellmann, 2015 .

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

T. Yamanaka, M. Ahn, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

M. Ahn, Dong-Wan Kim, J. Yang, 2017 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Cytokine Gene Expression Associated with Bone Destruction in Cholesteatoma Tissues

M. Ahn, Chulsoo Park, Yean Yu, 1999 .

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

N. Hanna, R. Kaiser, M. Ahn, 2013 .

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Short Report Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

J. Ahn, M. Ahn, Keunchil Park, 2019 .

Metabolic parameters on baseline 18F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

Kyung-Han Lee, J. Choi, M. Ahn, 2022, Frontiers in Medicine.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Edward S. Kim, H. Groen, E. Smit, 2022, JTO clinical and research reports.

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Jie Yang, C. Gridelli, M. Ahn, 2022, Clinical lung cancer.

Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2020, Clinical Cancer Research.

High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.

M. Ahn, E. Cho, J. H. Lee, 2003, Journal of Korean medical science.

High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma

M. Ahn, E. Cho, J. H. Lee, 2003 .

Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck.

M. Ahn, Keunchil Park, Yeon-Hee Park, 2011, Oral oncology.

Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study.

M. Ahn, S. Im, Junghye Choi, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Myung Ah Lee, M. Ahn, Tae-You Kim, 2007, Cancer Chemotherapy and Pharmacology.

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer

M. Ahn, Keunchil Park, S. Lim, 2020, The Korean journal of internal medicine.

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.

H. Groen, A. Chella, M. Ahn, 2013 .

9112 POSTER AVAPERL1 (MO22089) – Interim Safety of Maintenance (mtc) Bevacizumab (bev) + Pemetrexed (pern) in Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

M. Ahn, J. Burgers, F. Barlesi, 2011 .

Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.

P. Ascierto, M. Ahn, P. Ott, 2017 .

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S. Ou, M. Ahn, N. Segal, 2016 .

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2022, JTO clinical and research reports.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

A. Drilon, T. Wilson, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)

M. Ahn, Dong-Wan Kim, J. Cho, 2021, Cancer.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors.

E. Dmitrovsky, V. Rusch, M. Moasser, 1995, Oncogene.

Clinical Prognostic Factors and Treatment Outcome of Aggressive Non-Hodgkin's Lymphoma in Elderly Patients.

M. Ahn, I. S. Kim, J. Choi, 2001, Cancer research and treatment : official journal of Korean Cancer Association.

A Case of Severe Chronic Active Epstein-Barr Virus Infection with T-cell lymphoproliferative Disorder

M. Ahn, Chan Kum Park, I. Kim, 2004, The Korean journal of internal medicine.

A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors

Yong Soo Choi, Su Jin Lee, J. Ahn, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.

Su Jin Lee, J. Ahn, M. Ahn, 2012 .

A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management

M. Ahn, Y. Shim, J. Lee, 2007, British Journal of Cancer.

Outcome of Adult Severe or Very Severe Aplastic Anemia Treated with Immunosuppressive Therapy Compared with Bone Marrow Transplantation: Multicenter Trial

M. Ahn, J. H. Lee, Junghye Choi, 2003, International journal of hematology.

Postsplenectomy Recurrence of Thrombocytopenia with an Accessory Spleen

Sung Hyun Park, M. Ahn, Y. Choi, 2004, The Korean journal of internal medicine.

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC

Jie Yang, M. Ahn, K. Wilner, 2022, JTO clinical and research reports.

Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Jie Yang, S. Gettinger, M. Ahn, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

A. Drilon, G. Demetri, M. Ahn, 2021, ESMO open.

Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

M. Ahn, Se-Hoon Lee, H. Jung, 2022, PloS one.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy.

M. Ahn, Jiyun Lee, 2021, Cancer treatment reviews.

Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy.

Su Jin Lee, M. Ahn, Keunchil Park, 2016, Japanese journal of clinical oncology.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

M. Ahn, T. Mok, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating entrectinib as a treatment option for non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Expert opinion on pharmacotherapy.

9076 POSTER An Interim Analysis of Health-Related Quality of Life (HRQoL) in Patients With Non-Squamous Non-Small-Cell Lung Cancer (nsNSCLC) Receiving Bevacizumab Vs Bevacizumab+Pemetrexed for Maintenance Therapy in AVAPERL 1

M. Ahn, S. Walzer, F. Barlesi, 2011 .

Prognostic Significance of Pseudotime from Texture Parameters of FDG PET/CT in Locally Advanced Non-Small-Cell Lung Cancer with Tri-Modality Therapy

J. Choi, M. Ahn, Hojoong Kim, 2022, Cancers.

Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke.

M. Ahn, Gyeong-Moon Kim, O. Bang, 2019, Stroke.

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.

Yong Soo Choi, M. Ahn, Keunchil Park, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications

M. Ahn, D. Han, Y. Noh, 2001, Experimental & Molecular Medicine.

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, iScience.

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Jie Yang, M. Ahn, T. Mok, 2020 .

Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations.

M. Ahn, T. Mok, S. Peters, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

M. Ahn, T. Mok, F. Shepherd, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.

J. Choi, M. Ahn, Keunchil Park, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Shibing Deng, M. Ahn, Joungho Han, 2014, The Journal of molecular diagnostics : JMD.

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

Ying Cheng, M. Ahn, T. Mok, 2020 .

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Su Jin Lee, J. Ahn, M. Ahn, 2012, Lung cancer.

Predicting Lung Cancer in Korean Never-Smokers with Polygenic Risk Scores

J. Yim, M. Ahn, S. Jee, 2022, bioRxiv.

A Case of NK/T-Cell Lymphoma Complicated by a Squamous Cell Carcinoma of Hard Palate during Combination Chemotherapy and Radiation Therapy

M. Ahn, Junghye Choi, H. Lee, 2002, The Korean journal of internal medicine.

A case of prostate cancer in 34 year old man presenting with generalized lymphadenopathy mimicking malignant lymphoma.

M. Ahn, S. Oh, S. Jang, 1997, Journal of Korean medical science.

Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis.

M. Ahn, Junghye Choi, S. Kim, 2002, Journal of Korean medical science.

Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy

M. Ahn, Keunchil Park, J. Noh, 2016, Head & neck.

First‐Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never‐Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA2_PRGEFITINIB/CHEMOTHERAPY VS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER PROGRESSION ON FIRST-LINE GEFITINIB: THE PHASE III, RANDOMISED IMPRESS STUDY

M. Ahn, T. Mok, Jin-Ji Yang, 2014 .

Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study

J. Ahn, M. Ahn, Yoon-La Choi, 2022, Precision and Future Medicine.

Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia

M. Ahn, E. Cho, J. H. Lee, 2022, The Korean journal of internal medicine.

Long-term follow-up results of cytarabine-contain-ing chemotherapy for acute promyelocytic leukemia Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia

M. Ahn, E. Cho, J. H. Lee, 2022 .

Impact of environmental tobacco smoke (ETS) on ALK rearrangements in never smokers (NS) with non-small cell lung cancer (NSCLC): Analyses on a prospective multinational ETS registry.

S. Ou, M. Ahn, M. Ando, 2013 .

Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma

J. Machiels, K. Harrington, M. Ahn, 2018, Clinical Trials.

A Case of Erythema Nodosum and Serositis Associated with Myelodysplastic Syndrome

M. Ahn, Junghye Choi, I. Kim, 2005, The Korean journal of internal medicine.

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors

Su Jin Lee, Jung-Il Lee, D. Nam, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2014, European journal of cancer.

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2015 .

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2022, Cancer medicine.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

C. Gridelli, S. Gettinger, M. Ahn, 2018, The New England journal of medicine.

Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.

J. Machiels, K. Harrington, M. Ahn, 2020, Journal of the National Cancer Institute.

Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy

M. Ahn, S. Bae, J. Jun, 2005, Rheumatology International.

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sin-Ho Jung, J. Ahn, M. Ahn, 2018, British Journal of Cancer.

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Jie Yang, M. Ahn, T. Mok, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

M. Ahn, E. Felip, S. Ramalingam, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.

J. Ahn, M. Ahn, Keunchil Park, 2022, International journal of radiation oncology, biology, physics.

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.

M. Ahn, W. Park, V. Anagnostou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke

M. Ahn, C. Chung, Gyeong-Moon Kim, 2018, Stroke.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Sin-Ho Jung, Ho Yun Lee, J. Ahn, 2016, Oncotarget.

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Oncotarget.

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

J. Choi, M. Ahn, Keunchil Park, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).

Sung-Bae Kim, M. Ahn, Keunchil Park, 2012, European journal of cancer.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer Chemotherapy and Pharmacology.

Pleural Mesothelioma: An Institutional Experience of 66 Cases

M. Ahn, Joungho Han, Jhingook Kim, 2014, Korean journal of pathology.

Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.

E. Dmitrovsky, M. Moasser, M. Ahn, 1995, Oncogene.

Mutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs.

C. Ki, M. Ahn, Jong-Won Kim, 2011, The Journal of molecular diagnostics : JMD.

Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14‐01)

M. Ahn, Keunchil Park, J. Lee, 2017, Cancer.

Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland.

M. Ahn, Keunchil Park, Y. Ko, 2012, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

M. Ahn, Keunchil Park, Y. Ko, 2014, Journal of Translational Medicine.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

A. Drilon, A. Shaw, S. Ou, 2018, Cancer discovery.

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Jung-Il Lee, Y. Suh, J. Ahn, 2020, Nature Communications.

Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy

M. Ahn, Y. Son, C. Baek, 2023, Cancers.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

M. Ahn, Yi-long Wu, E. Felip, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation.

E. Dmitrovsky, V. Rusch, M. Ahn, 1996, Oncogene.

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

A. Drilon, A. Shaw, S. Ou, 2016 .

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung Kyoon Choi, Manel Esteller, Myung-Ju Ahn, 2019, Nature Communications.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

B. Teh, M. Ahn, B. Cho, 2016, Scientific Reports.

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Su Kyung Choi, M. Ahn, Sang-We Kim, 2021, Journal of Cancer Research and Clinical Oncology.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Edward S. Kim, N. Reinmuth, M. Ahn, 2020, JAMA oncology.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2017, Cancer Chemotherapy and Pharmacology.

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

M. Ahn, E. Felip, K. Emancipator, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.

Sin-Ho Jung, M. Ahn, Keunchil Park, 2016, European journal of cancer.

Comparative effectiveness of bevacizumab plus cisplatin‐based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non‐squamous non‐small cell lung cancer patients applying real‐life outcomes

Stefan Walzer, Myung-Ju Ahn, M. Ahn, 2011, Asia-Pacific journal of clinical oncology.

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

M. Ahn, E. Cho, S. Shreeve, 2021 .

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

J. Ahn, M. Ahn, E. Cho, 2019, The Lancet. Oncology.

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.

J. Barrett, M. Ahn, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.

M. Ahn, T. John, Aliki Taylor, 2021, Cancer epidemiology.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

M. Ahn, Yuh-Min Chen, J. Yang, 2012, Lung cancer.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Sung-Bae Kim, Y. Doki, M. Okada, 2019, The Lancet. Oncology.

Pembrolizumab for the treatment of non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2016, Expert opinion on biological therapy.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Jeong Eon Lee, P. Park, H. Kim, 2017, Nature Communications.

Topological Transformation‐Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism

Seung Won Shin, Soong Ho Um, Sang Hun Chun, 2019, Advanced biosystems.

Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients

M. Ahn, Hojoong Kim, O. Kwon, 2022, Journal of clinical medicine.

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

J. Ahn, M. Ahn, Keunchil Park, 2020, In Vivo.

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical lung cancer.

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

J. Ahn, M. Ahn, Keunchil Park, 2018, PloS one.

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)

Ho Yun Lee, J. Ahn, M. Ahn, 2018, Journal of pathology and translational medicine.

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert review of molecular diagnostics.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert opinion on drug safety.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

J. Ahn, M. Ahn, Keunchil Park, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Joon-Oh Park, J. Francis, M. Ahn, 2016, Oncotarget.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Sung-Bae Kim, K. Harrington, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC

M. Ahn, Y. Ko, Y. Son, 2020, Scientific Reports.

Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer

Jeon Yeob Jang, Sang Gyu Park, Joon Young Choi, 2009, Clinical Cancer Research.

Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial.

J. Machiels, K. Harrington, M. Ahn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

D. Nam, J. Ahn, M. Ahn, 2019, BMC Ophthalmology.

Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells.

Ki-Hwan Lee, Dong-Hyun Yu, Joon-Ik Ahn, 2002, Biochemical and biophysical research communications.

Imaging , Diagnosis , Prognosis Metabolic Tumor Volume of [ 18 F ]-Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer

S. Hyun, J. Choi, M. Ahn, 2009 .

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.

J. Ahn, M. Ahn, Keunchil Park, 2017 .

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of Cancer Research and Clinical Oncology.

Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

Donggeun Yoo, J. Ahn, M. Ahn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma

J. H. Kim, J. Ahn, M. Ahn, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

Seung Won Shin, Soong Ho Um, Kisuk Yang, 2017, Scientific Reports.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

J. Ahn, M. Ahn, Se-Hoon Lee, 2023, Journal for ImmunoTherapy of Cancer.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI‐906) or Placebo in Chemotherapy‐Naive Patients With Non–Small‐Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

C. Rudin, M. Ahn, P. Sunpaweravong, 2017, Clinical lung cancer.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

M. Ahn, Keunchil Park, T. Mok, 2016, JAMA oncology.

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer

M. Ahn, S. Lim, 2018, The Korean journal of internal medicine.

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.

M. Ahn, Jong-Mu Sun, J. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Ho Yun Lee, J. Ahn, M. Ahn, 2013, Anticancer research.

PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15

M. Ahn, E. Shin, Hoyoung Lee, 2020, Cellular & Molecular Immunology.

A new KIT gene mutation in thymic cancer and a promising response to imatinib.

J. Ahn, M. Ahn, Keunchil Park, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers

M. Ahn, Hojoong Kim, O. Kwon, 2013, Supportive Care in Cancer.

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight

Ho Yun Lee, M. Ahn, Keunchil Park, 2011, Cancer Chemotherapy and Pharmacology.

Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer

Ho Yun Lee, M. Ahn, Keunchil Park, 2020, Respiratory Research.

Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.

M. Ahn, Y. Shim, K. Lee, 2019, Lung cancer.

Phospho‐Stat3 expression and correlation with VEGF, p53, and Bcl‐2 in gastric carcinoma using tissue microarray

M. Ahn, Junghye Choi, I. Kim, 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Jae Cheol Lee, Jih-Hsiang Lee, F. Siddiqui, 2017, Oncotarget.

Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2013, PloS one.

Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal Growth Factor Receptor Inhibition in Lung Cancer

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013 .

JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology.

Joon Seol Bae, Ki-Wook Lee, Hyun-Tae Shin, 2019, The Journal of molecular diagnostics : JMD.

Junction Location Identifier (JuLI)

M. Ahn, Keunchil Park, W. Park, 2019 .

JuLI: accurate detection of DNA fusions in clinical sequencing for precision oncology

Joon Seol Bae, Ki-Wook Lee, Hyun-Tae Shin, 2019, bioRxiv.

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

M. Ahn, E. Cho, Siraj M. Ali, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

J. Ahn, M. Ahn, Keunchil Park, 2016, Oncotarget.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

I. Sohn, Sin-Ho Jung, J. Ahn, 2010, Lung cancer.

Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

Y. Shentu, M. Ahn, M. Dolled-Filhart, 2016 .

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer

M. Ahn, S. C. Lee, I. Hwang, 2006, British Journal of Cancer.

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and / or Metastatic Squamous Cell Carcinoma of Head and Neck

Min Goo Lee, S. Paik, M. Ahn, 2015 .

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Min Goo Lee, S. Paik, M. Ahn, 2014, Clinical Cancer Research.

Pulmonary Strongyloidiasis with alveolar hemorrhage in a patient receiving chemotherapy

M. Ahn, Keunchil Park, Hui-Young Lee, 2009 .

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences

Joon-Oh Park, M. Ahn, Keunchil Park, 2017, Oncotarget.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

J. Ahn, M. Ahn, Keunchil Park, 2016, Investigational New Drugs.

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

Shibing Deng, J. Christensen, J. Ahn, 2013, Genomics.

Clinical Aspects of Pregnancy and Delivery in Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP)

M. Ahn, Y. Won, Junghye Choi, 2005, The Korean journal of internal medicine.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

J. Ahn, M. Ahn, Keunchil Park, 2015, Clinical Cancer Research.

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.

M. Ahn, Keunchil Park, E. Cho, 2015, Lung cancer.

1275PEFFICACY OF EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS) IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER EXCEPT BOTH EXON 19 DELETION AND EXON 21 L858R: A RETROSPECTIVE ANALYSIS IN KOREA.

M. Ahn, E. Cho, B. Cho, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.

M. Ahn, Joo‐Hang Kim, Junghye Choi, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2019, Investigational New Drugs.

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

J. Ahn, M. Ahn, Keunchil Park, 2019, Clinical lung cancer.

Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer

M. Ahn, H. Kim, 2018 .

Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series

M. Ahn, Keunchil Park, Y. Ko, 2015, Head & neck.

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

S. Ou, M. Ahn, A. Kubo, 2014, Front. Oncol..

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.

Ha Yeon Lee, J. Ahn, M. Ahn, 2013, Lung cancer.

Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.

Shibing Deng, J. Ahn, M. Ahn, 2013, The Journal of molecular diagnostics : JMD.

Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.

T. Mitsudomi, Youngwook Kim, M. Ahn, 2010, The Journal of molecular diagnostics : JMD.

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

S. Paik, M. Ahn, Keunchil Park, 2015, Oncotarget.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

J. Ahn, M. Ahn, Keunchil Park, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

J. Ahn, M. Ahn, Keunchil Park, 2012, Histology and histopathology.

Molecular Medicine in Practice The EGFR T 790 M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2012 .

Title : The EGFR T 790 M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor

Youngwook Kim, J. Ko, Z. Cui, 2011 .

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2018, Clinical pharmacology in drug development.

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Lung cancer.

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of pathology and translational medicine.

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Jie Yang, S. Gettinger, M. Ahn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Targeted Therapy in Lung Cancer

M. Ahn, 2014 .

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

H. Groen, M. Ahn, J. Aerts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

G. Giaccone, M. Socinski, M. Ahn, 2017, Lung cancer.

Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2020 .

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas.

M. Ahn, Junghye Choi, S. Jang, 2002, Journal of Korean medical science.

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of the 5,10-methylenetetrahydrofolate reductase (MTHFR C677T and A1298C) polymorphisms in Korean patients with adult acute lymphoblastic leukemia.

M. Ahn, N. Kim, Y. Min, 2007, Anticancer research.

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design.

E. Smit, M. Ahn, Gregory Riely, 2021, Future oncology.

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).

N. Reinmuth, M. Ahn, F. Shepherd, 2021, Clinical lung cancer.

ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.

Edward S. Kim, S. Ou, M. Ahn, 2021, Future oncology.

Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study.

M. Ahn, Keunchil Park, C. Yi, 2020, Annals of palliative medicine.

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Translational lung cancer research.

Correction to: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12

Sung-Bae Kim, M. Ahn, I. Hwang, 2020, Journal of Cancer Research and Clinical Oncology.

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12

Sung-Bae Kim, M. Ahn, I. Hwang, 2020, Journal of Cancer Research and Clinical Oncology.

Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

J. Ahn, M. Ahn, Keunchil Park, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

M. Ahn, E. Cho, Dong-Wan Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2020, European journal of cancer.

Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer.

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.

J. Ahn, M. Ahn, Keunchil Park, 2020, Japanese journal of clinical oncology.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

Ho Yun Lee, J. Ahn, M. Ahn, 2019, International journal of cancer.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

M. Ahn, Keunchil Park, M. Chung, 2019, Clinical lung cancer.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Charu Aggarwal, Myung-Ju Ahn, Edward B Garon, 2019, The Lancet. Respiratory medicine.

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Cancer Research and Clinical Oncology.

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2020, BMJ Open.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

J. Ahn, M. Ahn, Keunchil Park, 2015, Cancer Chemotherapy and Pharmacology.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

M. Ahn, T. Mok, H. Onishi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characteristics and outcomes of ALK+ non‐small cell lung cancer patients in Korea

M. Ahn, Keunchil Park, S. Lim, 2017, Asia-Pacific journal of clinical oncology.

LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

J. Machiels, K. Harrington, M. Ahn, 2017 .

Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Ho Yun Lee, M. Ahn, Keunchil Park, 2015, Clinical lung cancer.

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Ha Yeon Lee, Sin-Ho Jung, J. Ahn, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2010, Clinical Cancer Research.

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib for the treatment of non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2017, Expert opinion on pharmacotherapy.

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

M. Ahn, Dong-Wan Kim, B. Cho, 2016, Oncotarget.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs.

J. Ahn, M. Ahn, Keunchil Park, 2015, Lung cancer.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.

You Lu, Haiyi Jiang, Kazuhiko Nakagawa, 2015, The Lancet. Oncology.

Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer.

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild‐type nonsmall cell lung cancer treated with EGFR‐tyrosine kinase inhibitors

J. Ahn, M. Ahn, Keunchil Park, 2011, Cancer.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Woo Yong Lee, Kyunghee Park, Kyoung-Mee Kim, 2017, Nature Communications.

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Telomerase activity in benign and malignant human thyroid nodules

M. Ahn, H. Lee, K. Tae, 1997, Experimental & Molecular Medicine.

Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study

M. Ahn, Seonwoo Kim, C. Chung, 2016, Journal of stroke.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

A. Chella, M. Ahn, Joo‐Hang Kim, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer

M. Ahn, Keunchil Park, Jong-Mu Sun, 2012, Clinical Medicine Insights. Oncology.

Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

I. Sohn, Ho Yun Lee, M. Ahn, 2019, Scientific Reports.

Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung.

Youngwook Kim, Z. Cui, J. Ahn, 2009, Anticancer research.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy

Youngwook Kim, J. Ahn, M. Ahn, 2011, Journal of Cancer Research and Clinical Oncology.

T He Differential G Ene Expression Profiles Betw Een Sensitive and Resistant Breast C Ancer C Ells to a Driam Ycin by Cdn a M Icroarray

M. Ahn, Junghye Choi, J. Jang, 2010 .

The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray.

M. Ahn, Junghye Choi, J. Jang, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.

J. Ahn, M. Ahn, Keunchil Park, 2021, European journal of cancer.

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

J. Ahn, M. Ahn, Keunchil Park, 2020, European journal of immunology.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

A. Drilon, T. Wilson, C. Chung, 2019, The Lancet. Oncology.

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Joon-Oh Park, J. Ahn, M. Ahn, 2020, Expert Opinion on Investigational Drugs.

Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial

Sung-Bae Kim, Q. Park, M. Ahn, 2002, International journal of hematology.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Investigational New Drugs.

Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.

P. Jänne, M. Ahn, B. Cho, 2022, Journal of Thoracic Oncology.

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Jie Yang, M. Tsuboi, M. Ahn, 2023, Targeted Oncology.

Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

M. Ahn, D. Camidge, Geoffrey Liu, 2020 .

M. Ahn, Gyeong-Moon Kim, O. Bang, 2020, Journal of stroke.

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2021, Investigational New Drugs.

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2‐Positive Non‐Small Cell Lung Cancer

Sin-Ho Jung, J. Ahn, M. Ahn, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.

J. Ahn, M. Ahn, Keunchil Park, 2014, Lung cancer.

Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma

M. Ahn, B. Keam, Joo-Kyung Kim, 2020, Processes.

Dna flow cytometry of stomach cancer. Prospective correlation with clinicopathologic findings

M. Ahn, C. Suh, Jung Shin Lee, 1993, Cancer.

Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09)

J. Ahn, M. Ahn, K. Park, 2018, Journal of Thoracic Oncology.

Prognostic value of volumetric metabolic parameters measured by [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer

J. Choi, M. Ahn, Keunchil Park, 2014, Cancer Imaging.

Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

S. Ou, M. Ahn, M. Ando, 2017, Clinical lung cancer.

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment

Su Jin Lee, J. Ahn, M. Ahn, 2009, Cancer.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.

J. Y. Lee, D. Na, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

J. Ahn, M. Ahn, Keunchil Park, 2010, Oncology.

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

P. Jänne, L. Sequist, T. Mitsudomi, 2018, Cancer.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer

M. Ahn, W. Park, Chung Lee, 2021, BMB reports.

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases

M. Ahn, Joungho Han, Yoon-La Choi, 2016, Journal of pathology and translational medicine.

Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR

S. Kim, M. Ahn, Hyung-Jin Kim, 2020, Journal of Neuro-Oncology.

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

M. Ahn, E. Cho, B. Cho, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

J. Ahn, M. Ahn, Se-Hoon Lee, 2022, Cancer research and treatment.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

J. Machiels, M. Ahn, T. Seiwert, 2016 .

Expression of cyclin dependent kinase inhibitor p21WAF1 alone and in combination with p27KIP1 shows prognostic value in gastric carcinoma.

M. Ahn, G. Kong, S. Paik, 1998, Journal of Korean medical science.

Absence of Clinical Prognostic Value of Vascular Endothelial Growth Factor and Microvessel Density in Multiple Myeloma

M. Ahn, Junghye Choi, S. Jang, 2002, International journal of hematology.

Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report.

M. Ahn, H. Kim, Hansang Lee, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.

M. Ahn, I. Chitapanarux, A. Chan, 2016, Oral oncology.

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

P. Jänne, K. O'Byrne, Michael Thomas, 2012 .

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

J. Ahn, M. Ahn, Keunchil Park, 2012, Human Genetics.

The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations

J. Ahn, M. Ahn, Keunchil Park, 2011, Human Genetics.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Abstract IA36: Treatment strategies to overcome EGFR TKI resistance.

M. Ahn, 2014 .

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Lee, M. Ahn, Y. Bang, 2017 .

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

M. Ahn, D. Rasco, E. Chartash, 2020, Annals of Oncology.

A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2012, International journal of biomedical science : IJBS.

Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.

Z. Cui, J. Ahn, M. Ahn, 2009, Cancer research and treatment : official journal of Korean Cancer Association.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Su Jin Lee, J. Ahn, M. Ahn, 2014, Cancer Chemotherapy and Pharmacology.

Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance.

M. Ahn, S. Jang, E. K. Hong, 1998, Journal of Korean medical science.

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Sin-Ho Jung, M. Ahn, Keunchil Park, 2017 .

Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN).

S. Paik, M. Ahn, S. Lim, 2015 .

Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach

I. Sohn, Ho Yun Lee, M. Ahn, 2018, Scientific Reports.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.

Sin-Ho Jung, J. Ahn, M. Ahn, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer

M. Ahn, Keunchil Park, W. Park, 2015, PLoS genetics.

Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

M. Ahn, T. Mok, F. Shepherd, 2019, Annals of Oncology.

Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Shaw, M. Ahn, L. Crinò, 2012 .

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.

J. Ahn, M. Ahn, Keunchil Park, 2009, Lung cancer.

Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis

M. Ahn, S. Hwang, T. Shin, 2021, Biomedicines.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).

Sung-Bae Kim, Sin-Ho Jung, M. Ahn, 2016, Radiotherapy and Oncology.

Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis

M. Ahn, Joungho Han, O. Kwon, 2023, Scientific Reports.

Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.

Jie Yang, S. Toyooka, Y. Yatabe, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Jie Yang, S. Toyooka, Y. Yatabe, 2022 .

A case of petrous carotid artery pseudoaneurysm presenting with epistaxis after radiotherapy in a patient with nasopharyngeal cancer

Su Jin Lee, M. Ahn, Keunchil Park, 2010 .

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.

S. Gettinger, M. Ahn, E. Felip, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical value of cyclooxygenase-2 expression in human breast carcinoma.

Sung-Bae Kim, S. Ahn, M. Ahn, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray

J. Ahn, M. Ahn, Keunchil Park, 2010, Cancer.

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

J. Ahn, M. Ahn, Keunchil Park, 2020, Nature Communications.

Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.

M. Ahn, Keunchil Park, Y. Shim, 2016, Lung cancer.

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer

Ho Yun Lee, M. Ahn, Jeonghee Cho, 2021, Cancer research and treatment.

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, Cancer Chemotherapy and Pharmacology.

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

T. Mitsudomi, M. Ahn, Dong-Wan Kim, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).

T. Yamanaka, M. Ahn, Yi-long Wu, 2016 .

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

J. Ahn, M. Ahn, Keunchil Park, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

A. Drilon, S. Ou, A. Shaw, 2019, Journal of Clinical Oncology.

Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis

M. Ahn, T. Mok, J. Soria, 2016 .

OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

L. Sequist, M. Ahn, Chun-Ming Tsai, 2017 .

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Jie Yang, L. Sequist, M. Ahn, 2022, Cancer discovery.

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

M. Ahn, E. Felip, K. Emancipator, 2015 .

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2009, Medical oncology.

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

J. Ahn, M. Ahn, Keunchil Park, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.

M. Ahn, Yi-long Wu, F. Shepherd, 2018 .

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Jie Yang, J. Barrett, M. Ahn, 2023, Nature Communications.

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Sung-Bae Kim, Y. Doki, M. Okada, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer

J. Choi, M. Ahn, Keunchil Park, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery

M. Tsuboi, C. Swanton, M. Ahn, 2021 .

1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

A. Drilon, M. Ahn, R. Doebele, 2020 .

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer medicine.

Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

M. Ahn, Yoon-La Choi, Jong-Mu Sun, 2022, Cancer.

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis.

Ying Cheng, M. Ahn, T. Mok, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.

M. Cotreau, M. Ahn, E. Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

J. Ahn, M. Ahn, Keunchil Park, 2016, Oncotarget.

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

H. Groen, G. Scagliotti, H. Wakelee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of Clinical Oncology.

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

T. Mitsudomi, M. Ahn, Keunchil Park, 2014 .

Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma (ESCC).

M. Ahn, Dae-Ho Lee, B. Keam, 2019, Journal of Clinical Oncology.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

J. Ahn, M. Ahn, H. Cha, 2023, Advanced science.

Prognostic role of insulin‐like growth factor receptor‐1 expression in small cell lung cancer

J. Ahn, M. Ahn, Keunchil Park, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

M. Ahn, E. Felip, S. Ramalingam, 2019, Journal of Clinical Oncology.

Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer

Joon-Oh Park, M. Ahn, S. Park, 2018, Clinical colorectal cancer.

Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Kyung-Han Lee, J. Choi, M. Ahn, 2016, The British journal of radiology.

BJRD16109 1..8

Kyung-Han Lee, J. Choi, M. Ahn, 2016 .

A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.

J. Ahn, M. Ahn, Keunchil Park, 2016 .

Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.

M. Ahn, A. Nagrial, M. Satouchi, 2021, Lung Cancer.

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

N. Reinmuth, M. Ahn, N. Rizvi, 2019, Journal of Thoracic Oncology.

Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.

A. Drilon, A. Shaw, M. Ahn, 2019, Journal of Clinical Oncology.

Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study

J. Ahn, M. Ahn, Keunchil Park, 2016 .

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?

M. Ahn, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiomics Analysis of 18F-FDG PET/CT for Prognosis Prediction in Patients with Stage III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiation Therapy Followed by Surgery

J. Choi, M. Ahn, H. Pyo, 2023, Cancers.

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?

J. Ahn, M. Ahn, Keunchil Park, 2020, Biology.

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.

K. Harrington, M. Ahn, V. Grünwald, 2020, Oral oncology.

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.

J. Ahn, M. Ahn, Keunchil Park, 2011, Lung cancer.

Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).

P. Jänne, M. Ahn, Y. Ohe, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.

J. Ahn, M. Ahn, E. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS).

M. Ahn, Y. Wu, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The prognostic value of radiomic features from pre- and post-treatment 18F-FDG PET imaging in patients with nasopharyngeal carcinoma.

J. Choi, M. Ahn, S. Kim, 2023, Scientific reports.

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.

Edward J. Kim, N. Reinmuth, M. Ahn, 2019, Clinical Trials.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.

J. Ahn, M. Ahn, Keunchil Park, 2014, Lung cancer.

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

M. Ahn, A. Dechaphunkul, Y. Geng, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

Edward S. Kim, Dohoung Kim, S. Gettinger, 2017 .

Epstein-Barr virus-associated Hodgkin's disease following renal transplantation

M. Ahn, Junghye Choi, Y. Oh, 2006, The Korean journal of internal medicine.

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

S. Gettinger, M. Ahn, R. Camidge, 2019, Annals of Oncology.

Abstract CT303: The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm)MET-amplified NSCLC in the TATTON study

M. Ahn, B. Cho, Ji-Youn Han, 2020 .

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

J. Ahn, M. Ahn, Keunchil Park, 2016, Medical Oncology.

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

T. Powles, M. Ahn, M. Maio, 2018, Clinical Trials.

P3.01-023 First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice

M. Ahn, Kyoungsook Park, Jong-Mu Sun, 2017 .

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types

Y. L. Sung, Myung Ah Lee, M. Ahn, 2017, Supportive Care in Cancer.

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer.

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

J. Ahn, M. Ahn, Keunchil Park, 2020, Immune network.

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.

M. Ahn, Keunchil Park, Y. Shim, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective

J. Ahn, M. Ahn, Keunchil Park, 2013 .

OA 14.06 Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Drilon, M. Ahn, R. Doebele, 2017 .

Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years.

Kyung Soo Lee, Myung-Ju Ahn, Ho Yun Lee, 2010, Lung cancer.

Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: FDG Uptake and Risk Stratification

J. Choi, J. Ahn, M. Ahn, 2019, Clinical nuclear medicine.

Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy

J. Choi, M. Ahn, Jhingook Kim, 2022, Cancers.

CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3).

M. Ahn, T. Mok, Yi-long Wu, 2017 .

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).

M. Ahn, T. Mok, E. Felip, 2019, Journal of Clinical Oncology.

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Radiofrequency ablation for metastatic hepatic tumor in colorectal carcinoma.

M. Ahn, Junghye Choi, H. Rhim, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Recent Progress in Non-Small Cell Lung Cancer: Prime Time for Personalized Therapy

M. Ahn, 2014 .

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study.

N. Reinmuth, M. Ahn, F. Shepherd, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

M. Ahn, Keunchil Park, Se-Hoon Lee, 2021 .

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical Cancer Research.

KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.

M. Ahn, E. Felip, S. Ramalingam, 2017 .

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.

R. Herbst, M. Ahn, E. Felip, 2017 .

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

M. Ahn, N. Segal, A. Gupta, 2017 .

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

M. Ahn, E. Felip, S. Ramalingam, 2016 .

Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)

M. Ahn, E. Felip, K. Emancipator, 2015 .

Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.

Edward S. Kim, M. Ahn, S. Novello, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

M. Ahn, Keunchil Park, J. Lee, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Breast cancer survivors of different sexual orientations : which factors explain survivors ’ quality of life and adjustment ?

Y. S. Kim, M. Ahn, S. Jung, 2013 .

Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.

M. Ahn, Jeeyun Lee, S. Park, 2015, World journal of gastroenterology.

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.

S. Hyun, J. Choi, M. Ahn, 2015, AJR. American journal of roentgenology.

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Cancer research and treatment.

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2010, Lung cancer.

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

M. Ahn, Keunchil Park, W. Chang, 2018, The Korean journal of internal medicine.

Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria

M. Ahn, Soohyun Hwang, Joungho Han, 2016, Journal of pathology and translational medicine.

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2021 .

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

J. Ahn, M. Ahn, Keunchil Park, 2023, JAMA network open.

4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

M. Ahn, E. Felip, S. Ramalingam, 2018 .

MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017 .

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

J. Ahn, M. Ahn, Keunchil Park, 2021, Translational lung cancer research.

Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.

M. Ahn, Joungho Han, Yoon-La Choi, 2019, Pathology, research and practice.

Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

M. Ahn, E. Cho, Dong-Wan Kim, 2023, Cancer research and treatment.

Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

S. Gettinger, M. Ahn, D. Camidge, 2018 .

Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?

M. Ahn, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Joon-Oh Park, H. Kim, J. Ahn, 2015, Oncotarget.

Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.

M. Ahn, Junghye Choi, I. Kim, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early‐stage lung adenocarcinoma

M. Ahn, Y. Shim, Soohyun Hwang, 2023, Histopathology.

Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor.

Kyung-Han Lee, J. Ahn, M. Ahn, 2016, Lung cancer.

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.

Y. Yatabe, M. Ahn, K. Kerr, 2023, Lung cancer.

Detection of tumor cell contamination in peripheral blood by RT-PCR in gastrointestinal cancer patients.

M. Ahn, J. Ku, Y. S. Lee, 1999, Journal of Korean medical science.

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

L. Sequist, M. Ahn, W. Su, 2019, Annals of Oncology.

An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).

J. Ahn, M. Ahn, Keunchil Park, 2018 .

Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.

A. Drilon, G. Demetri, M. Ahn, 2020 .

Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?

J. Ahn, M. Ahn, Keunchil Park, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The association of epidermal growth factor receptor (EGFR) mutation and survival in N2(+) non-small cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

M. Ahn, Y. Shim, K. Park, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study.

M. Ahn, J. Sohn, I. Choi, 1998, Journal of Korean medical science.

Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study

M. Ahn, C. Chung, Gyeong-Moon Kim, 2016, PloS one.

Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

M. Ahn, Dae-Ho Lee, B. Keam, 2023, Cancer medicine.

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).

Ho Yun Lee, J. Ahn, M. Ahn, 2018 .

C3-06: ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small cell lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery

J. Ahn, M. Ahn, Keunchil Park, 2007 .

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

A. Drilon, S. Ou, M. Ahn, 2020 .

Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.

J. Ahn, M. Ahn, Keunchil Park, 2020 .

Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma

M. Ahn, Y. Y. Lee, I. Choi, 2005 .

LBA3A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC – UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

P. Jänne, M. Ahn, D. Planchard, 2015 .

Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression

Gyudo Lee, Kilho Eom, Heung Jae Park, 2017, Theranostics.

Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?

Jung-Il Lee, D. Kong, D. Nam, 2010, Lung cancer.

Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers

M. Ahn, Yuh-Seog Jung, Y. Son, 2023, Cancers.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy

J. Ahn, M. Ahn, Keunchil Park, 2014, Annals of Surgical Oncology.

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications.

Ho Yun Lee, M. Ahn, Keunchil Park, 2011, Radiology.

L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large‐cell neuroendocrine tumors

Youngwook Kim, Z. Cui, J. Ahn, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

M. Ahn, Keunchil Park, E. Cho, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

A. Drilon, M. Ahn, S. Rangaraju, 2017 .

Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

P. Park, H. Kim, W. Lee, 2017, Nature Communications.

CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology.

P. Postmus, M. Ahn, J. Jassem, 2012 .

A phase II study of doxorubicin and cisplatin combination chemotherapy for advanced hepatocellular carcinoma.

M. Ahn, Yeon-Hee Park, H. Song, 2005 .

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma

M. Ahn, Keunchil Park, Y. Shim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2014, The oncologist.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2015, The Oncologist.

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

P. Jänne, T. Mitsudomi, M. Ahn, 2015 .

Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ

Seung Won Shin, Soong Ho Um, Yong Taik Lim, 2017, Scientific Reports.

A Case of Steroid Refractory Acute GVHD Treated with IL-2 & TNF-αBlocker in a Myelodysplastic Syndrome Patient who Underwent Unrelated Allogeneic Stem Cell Transplantation

M. Ahn, Junghye Choi, Myungsook Chang, 2006 .

Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?

J. Seo, Ho Yun Lee, M. Ahn, 2012, Korean journal of radiology.

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.

M. Ahn, J. Ahn, J. Ji, 2015 .

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

A case of posttransplantation lymphoproliferative disease developed in renal transplant recipient and treated with rituximab.

M. Ahn, Chan Kum Park, Chan-Bum Choi, 2004 .

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

J. Ahn, M. Ahn, Keunchil Park, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

First-Line Alectinib vs. Brigatinib in Advanced NSCLC with ALK Rearrangement: Real-World Data.

J. Ahn, M. Ahn, Jong-Mu Sun, 2023, Cancer research and treatment : official journal of Korean Cancer Association.

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.

M. Ahn, B. Cho, S. How, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

S. Gettinger, S. Ou, M. Ahn, 2017 .

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

M. Ahn, G. Oxnard, R. Hartmaier, 2019, Journal of Clinical Oncology.

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Edward S. Kim, N. Reinmuth, M. Ahn, 2019, Journal of Clinical Oncology.

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial

Edward S. Kim, H. Groen, S. Gettinger, 2019, Annals of Oncology.

Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.

Edward S. Kim, S. Ou, M. Ahn, 2019, Journal of Clinical Oncology.

J. Machiels, K. Harrington, M. Ahn, 2018 .

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.

Y. Shentu, R. Herbst, M. Ahn, 2016 .

1348POverall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

S. Vowler, P. Jänne, T. Mitsudomi, 2017 .

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

M. Ahn, Keunchil Park, H. Jung, 2023, Cancer research and treatment.

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Jie Yang, M. Ahn, Dong-Wan Kim, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multimodal Treatments and Outcomes for Anaplastic Thyroid Cancer Before and After Tyrosine Kinase Inhibitor Therapy: A Real-World Experience.

M. Ahn, Keunchil Park, W. Park, 2021, European journal of endocrinology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer

J. Ahn, M. Ahn, Keunchil Park, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.

J. Ahn, M. Ahn, E. Cho, 2018 .

Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer.

H. Seol, Jung-Il Lee, D. Kong, 2016, World neurosurgery.

H. Groen, M. Ahn, J. Aerts, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Abstract CT034: Osimertinib plus selumetinib for patients (pts) withEGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

M. Ahn, Y. Ohe, H. Saka, 2019, Clinical Trials.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J. Ahn, M. Ahn, Keunchil Park, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.

Sin-Ho Jung, M. Ahn, Jong-Mu Sun, 2013, Annals of Oncology.

1354POsimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS)

M. Ahn, Y. Wu, C. Zhou, 2017 .

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

S. Gettinger, M. Ahn, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

E. Smit, M. Ahn, Gregory Riely, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21).

J. Ahn, M. Ahn, Keunchil Park, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Telomease Activity in Head and Neck Cancer

M. Ahn, Y. Noh, Yong-Sung Lee, 1995 .

Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

I. Sohn, Ho Yun Lee, M. Ahn, 2019, Scientific Reports.

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

J. Ahn, M. Ahn, Keunchil Park, 2023, Cancer research and treatment.

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Jie Yang, P. Jänne, E. Smit, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2023, Cancer.

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.

J. Ahn, M. Ahn, Soohyun Hwang, 2023, Journal of Thoracic Oncology.

A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial

M. Ahn, S. Lim, Keun-Wook Lee, 2023, Cancer research and treatment.

LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

A. Drilon, M. Ahn, R. Doebele, 2017 .

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.

Ying Cheng, M. Ahn, L. Xing, 2023, Journal of Clinical Oncology.